RxDoctor Payments Data

Jill Schmidt

Psychiatric/Mental Health · Long Beach, CANPI 1508825761

Payments from drug & device makers

$2,628in general payments, 2019–2025

Across 126 payments — averaging $20.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$538
  • Indivior Inc.$281
  • Otsuka America Pharmaceutical, Inc.$246
  • Alkermes, Inc.$111
  • Sunovion Pharmaceuticals Inc.$87
  • plus $67 from 2 others

What the payments were for

  • Food & beverage$2,57698%
  • Education$532%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,628 in reported general payments places this provider in the 80th percentile of 2,433 psychiatric/mental health providers in California.

See all psychiatric/mental health providers in California

Medicare billing

Part B allowed, 2024
$99,385
Medicare patients
166
Services billed
1,250

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate29$88,780
Aripiprazole OdtAripiprazole89$82,382
Risperidone OdtRisperidone191$56,775
Aripiprazole238$44,864
Lurasidone Hcl128$37,137
Olanzapine OdtOlanzapine162$20,128
NuedextaDextromethorphan Hbr/Quinidine12$18,541
Divalproex Sodium250$9,519
Quetiapine Fumarate389$7,724
Paliperidone ErPaliperidone20$6,425
BelsomraSuvorexant12$5,532
Haloperidol88$4,647
Bupropion XlBupropion Hcl132$3,497
Risperidone208$3,196
Buspirone Hcl158$2,917

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$1,300$88,78029 claims
Teva Pharmaceuticals USA, Inc.Loxapine$14$2,20523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,433 psychiatric/mental health providers in California.

Other psychiatric/mental health in Long Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →